Welcome to LookChem.com Sign In|Join Free

CAS

  • or

69408-81-7

Post Buying Request

69408-81-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

69408-81-7 Usage

Description

Amonafide is a DNA intercalator and topoisomerase II inhibitor, which is currently in clinical development for the treatment of neoplastic diseases. It functions as an antitumor agent, making it a promising candidate for cancer therapy.

Uses

Used in Oncology:
Amonafide is used as an antineoplastic agent for the treatment of neoplastic diseases. It works by intercalating into DNA and inhibiting topoisomerase II, which leads to the prevention of DNA replication and transcription, ultimately resulting in the death of cancer cells.
Used in Cancer Therapy:
Amonafide is used as a therapeutic agent in cancer treatment. Its mechanism of action involves the intercalation into DNA and inhibition of topoisomerase II, which disrupts the essential processes of DNA replication and transcription in cancer cells, thereby exerting an antineoplastic effect.

Biological Activity

amonafide is a novel topoisomerase ii inhibitor. topoisomerase ii plays critical roles including dna transcription, replication and chromosome segregation. though the biological functions of topoisomerase ii are important for insuring genomic integrity, the ability to interfere with topoisomerase ii and generate enzyme mediated dna damage is an effective strategy for cancer chemotherapy.

in vitro

amonafide intercalated with dna and disrupted the loading of topoisomerases. in contrast to the classic agents, amonafide was found to induce higher molecular weight fragmentation, resulting in the apoptosis without dna cleavage. amonafide was found to act in an atp-independent manner and seemed unlikely to induce the chromosome translocations associated with treatmentinduced leukemia [1].

in vivo

amonafide was found to be able to inhibit ip l1210 leukemia, with optimal increased life spans (ils) of 61% to 106% following single 16 mg/kg dosing on days 1 to 9. similar efficacy was noted against ip p388 murine leukemia and the sc implanted l1210 leukemia. additionally, amonafide demonstrated activity against two nonleukemic ip implanted murine tumors, the m5076 sarcoma and the b16 melanoma [2].

IC 50

4.67, 2.73, and 6.38 for ht-29, hela, and pc3 cells, respectively

references

[1] freeman cl,swords r,giles fj. amonafide: a future in treatment of resistant and secondary acute myeloid leukemia expert rev hematol.2012 feb;5(1):17-26. [2] saez r,craig jb,kuhn jg,weiss gr,koeller j,phillips j,havlin k,harman g,hardy j,melink tj, et al. phase i clinical investigation of amonafide. j clin oncol.1989 sep;7(9):1351-8.

Check Digit Verification of cas no

The CAS Registry Mumber 69408-81-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,9,4,0 and 8 respectively; the second part has 2 digits, 8 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 69408-81:
(7*6)+(6*9)+(5*4)+(4*0)+(3*8)+(2*8)+(1*1)=157
157 % 10 = 7
So 69408-81-7 is a valid CAS Registry Number.
InChI:InChI=1/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3

69408-81-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 5-amino-2-[2-(dimethylamino)ethyl]benzo[de]isoquinoline-1,3-dione

1.2 Other means of identification

Product number -
Other names Amonafidum [Latin]

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:69408-81-7 SDS

69408-81-7Relevant articles and documents

Real-Time Multi-Photon Tracking and Bioimaging of Glycosylated Theranostic Prodrugs upon Specific Enzyme Triggered Release

Calatrava-Pérez, Elena,Elmes, Robert B. P.,Gunnlaugsson, Thorfinnur,Lynch, Dylan M.,Marchetti, Luke A.,McManus, Gavin J.,Scanlan, Eoin M.,Williams, D. Clive

, (2021/12/09)

Real-time tracking of prodrug uptake, delivery and activation in vivo represents a major challenge for prodrug development. Herein, we demonstrate the use of novel glycosylated theranostics of the cancer pharmacophore Amonafide in highly-selective, enzyma

A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent

Ma, Jing,Li, Linrong,Yue, Kexin,Zhang, Zhansheng,Su, Shihao,Chen, Yutong,Yu, Lu,Zhang, Pengfei,Ma, Ruijuan,Li, Yingguang,Ma, Yinxia,Jia, Huinan,Wang, Chaojie,Wang, Jiajia,Xie, Songqiang

, (2021/05/10)

Disseminated tumors lead to approximately 90% of cancer-associated deaths especially for hepatocellular carcinoma (HCC), indicating the imperative need of antimetastatic drugs and the ineffectiveness of current therapies. Recently polyamine derivatives have been identified as a promising prospect in dealing with metastatic tumors. Herein, a novel class of naphthalimide-polyamine conjugates 8a-8d, 13a-13c, 17 and 21 were synthesized and the mechanism was further determined. The polyamine conjugate 13b displayed remarkably elevated anti-tumor and anti-metastatic effects (76.01% and 75.02%) than the positive control amonafide (46.91% and 55.77%) at 5 mg/kg in vivo. The underlying molecular mechanism indicated that in addition to induce DNA damage by up-regulating p53 and γH2AX, 13b also targeted lysosome to modulate polyamine metabolism and function in a totally different way from that of amonafide. Furthermore, the HMGB1/p62/LC3II/LC3I and p53/SSAT/β-catenin pathways were mainly involved in the inhibition of 13b-induced HCC metastasis by targeting polyamine transporters (PTs) overexpressed in HCC. At last, 13b down-regulated the concentrations of Put, Spd and Spm by modulating polyamine metabolism key enzymes SSAT and PAO, which favored the suppression of fast growing tumor cells. Taken together, our study implies a promising strategy for naphthalimide conjugates to treat terminal cancer of HCC by targeting autophagy and tumor microenvironment with reduced toxicities and notable activities.

Design, synthesis, and evaluation of novel 3-carboranyl-1,8-naphthalimide derivatives as potential anticancer agents

Rykowski, Sebastian,Gurda-Wo?na, Dorota,Orlicka-P?ocka, Marta,Fedoruk-Wyszomirska, Agnieszka,Giel-Pietraszuk, Ma?gorzata,Wyszko, Eliza,Kowalczyk, Aleksandra,St?czek, Pawe?,Bak, Andrzej,Kiliszek, Agnieszka,Rypniewski, Wojciech,Olejniczak, Agnieszka B.

, p. 1 - 43 (2021/03/15)

We synthesized a series of novel 3-carboranyl-1,8-naphthalimide derivatives, mitonafide and pinafide analogs, using click chemistry, reductive amination and amidation reactions and investigated their in vitro effects on cytotoxicity, cell death, cell cycle, and the production of reactive oxygen species in a HepG2 cancer cell line. The analyses showed that modified naphthalic anhydrides and naphthalimides bearing ortho-or meta-carboranes exhibited diversified activity. Naphthalimides were more cytotoxic than naphthalic anhydrides, with the highest IC50 value determined for compound 9 (3.10 μM). These compounds were capable of inducing cell cycle arrest at G0/G1 or G2M phase and promoting apoptosis, autophagy or ferroptosis. The most promising conjugate 35 caused strong apoptosis and induced ROS production, which was proven by the increased level of 2′-deoxy-8-oxoguanosine in DNA. The tested conjugates were found to be weak topoisomerase II inhibitors and classical DNA intercalators. Compounds 33, 34, and 36 fluorescently stained lysosomes in HepG2 cells. Additionally, we performed a similarity-based assessment of the property profile of the conjugates using the principal component analysis. The creation of an inhibitory profile and descriptor-based plane allowed forming a structure–activity landscape. Finally, a ligand-based comparative molecular field analysis was carried out to specify the (un)favorable structural modifications (pharmacophoric pattern) that are potentially important for the quantitative structure– activity relationship modeling of the carborane–naphthalimide conjugates.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 69408-81-7